VytronUS, Inc., a Sunnyvale, CA-based medical device company developing novel technologies for the treatment of cardiac arrhythmias, secured $31.6m in Series B financing.
The round was led by Apple Tree Partners, with participation from new investors BioStar Ventures, Windham Venture Partners and a strategic investor alongside New Enterprise Associates and other existing investors. In conjunction with the funding, David McIntyre and Sami Hamade, representing Apple Tree Partners, an Hank Kucheman, representing BioStar Ventures, will join VytronUS’s Board of Directors.
The company intends to use the funds for development and validation of proprietary Low-Intensity Collimated Ultrasound (LICU) Cardiac Imaging and Ablation System to treat atrial fibrillation and other arrhythmias in forthcoming clinical trials.
Founded in 2006 and led by Michael Pederson, CEO, who will be stepping down later this quarter to lead Abbott’s newly-formed electrophysiology business, VytronUS is developing an integrated imaging and ablation system for cardiac electrophysiologists. The company has developed a catheter-based ablation platform employing Low-Intensity Collimated Ultrasound (LICU™), which allows for non-contact energy delivery and is capable of quickly producing high-resolution images of cardiac anatomy.